MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program

Blood

Volumn 122, Issue 15, 2013, Pages 2630-2640

  Xu Monette, Zijun Y ^a   Møller, Michael B ^b   Tzankov, Alexander ^c   Montes Moreno, Santiago ^d   Hu, Wenwei ^e   Manyam, Ganiraju C ^a   Kristensen, Louise ^b   Fan, Lei ^f   Visco, Carlo ^g   Dybkær, Karen ^h   Chiu, April ⁱ   Tam, Wayne ^j   Zu, Youli ^k   Bhagat, Govind ^l   Richards, Kristy L ^m   Hsi, Eric D ⁿ   Choi, William W L ^o   Van Krieken, J Han ^p   Huang, Qin ^q   Huh, Jooryung ^r   Ai, Weiyun ^s   Ponzoni, Maurilio ^t   Ferreri, Andrés J M ^t   Wu, Lin ^u   Zhao, Xiaoying ^v   Bueso Ramos, Carlos E ^a   Wang, Sa A ^a   Go, Ronald S ^w   Li, Yong ^x,y   Winter, Jane N ^z   Piris, Miguel A ^d   Medeiros, L Jeffrey ^a   Young, Ken H ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^f THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^g SAN BORTOLO HOSPITAL   (Italy)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k HOUSTON METHODIST HOSPITAL   (United States)

^l NewYork Presbyterian Hospital   (United States)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF HONG KONG   (Hong Kong)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^r University of Ulsan College of Medicine   (South Korea)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t SAN RAFFAELE HOSPITAL   (Italy)

^u ROCHE MOLECULAR SYSTEMS   (United States)

^v THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^w MAYO CLINIC   (United States)

^x UNIVERSITY OF LOUISVILLE   (United States)

^y SHANGHAITECH UNIVERSITY   (China)

^z NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; AUTOPHAGY RELATED PROTEIN 7; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; LACTATE DEHYDROGENASE; P21 ACTIVATED KINASE 2; PREDNISONE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MDM2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL OUTCOME; DIFFUSE LARGE B CELL LYMPHOMA; DNA REPAIR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY; TUMOR VOLUME; UPREGULATION; AGED; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHENOTYPE; PREDNISONE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 84891606259     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-473702     Document Type: Article

References (50)

1. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16):3668-3683.
2. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res. 2003;1(14):993-1000.
3. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res. 2004;2(1):1-8.
4. Wang P, Lushnikova T, Odvody J, Greiner TC, Jones SN, Eischen CM. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene. 2008;27(11):1590-1598.
5. Capoulade C, Bressac-de Paillerets B, Lefrère I, et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene. 1998;16(12): 1603-1610.
6. Møller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol. 1999;12(11):1010-1016.
7. Solenthaler M, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica. 2002;87(11):1141-1150.
8. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr CJ, Roussel MF. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 2002;62(4): 1222-1230.
9. Wagner J, Ma L, Rice JJ, Hu W, Levine AJ, Stolovitzky GA. p53-Mdm2 loop controlled by a balance of its feedback strength and effective dampening using ATM and delayed feedback. Syst Biol (Stevenage). 2005;152(3):109-118.
10. Ciliberto A, Novak B, Tyson JJ. Steady states and oscillations in the p53/Mdm2 network. Cell Cycle. 2005;4(3):488-493.
11. Pang LY, Scott M, Hayward RL, et al. p21(WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle. 2011;10(6):932-950.
12. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010;17(1):93-102.
13. Lev Baror R, Maya R, Segel LA, Alon U, Levine AJ, Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA. 2000;97(21):11250-11255.
14. Monk NA. Oscillatory expression of Hes1, p53, and NF-kappaB driven by transcriptional time delays. Curr Biol. 2003;13(16):1409-1413.
15. Hamstra DA, Bhojani MS, Griffin LB, Laxman B, Ross BD, Rehemtulla A. Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res. 2006; 66(15):7482-7489.
16. Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet. 2004;36(2):147-150.
17. Ma L, Wagner J, Rice JJ, Hu W, Levine AJ, Stolovitzky GA. A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci USA. 2005;102(40):14266-14271.
18. Proctor CJ, Gray DA. Explaining oscillations and variability in the p53-Mdm2 system. BMC Syst Biol. 2008;2:75.
19. Geva-Zatorsky N, Rosenfeld N, Itzkovitz S, et al. Oscillations and variability in the p53 system. Mol Syst Biol. 2006;2:2006.0033.
20. Puszyński K, Hat B, Lipniacki T. Oscillations and bistability in the stochastic model of p53 regulation. J Theor Biol. 2008;254(2):452-465.
21. Hunziker A, Jensen MH, Krishna S. Stress-specific response of the p53-Mdm2 feedback loop. BMC Syst Biol. 2010;4:94.
22. Ouattara DA, Abou-Jaoudé W, Kaufman M. From structure to dynamics: frequency tuning in the p53-Mdm2 network. II Differential and stochastic approaches. J Theor Biol. 2010;264(4): 1177-1189.
23. Kim DH, Rho K, Kim S. A theoretical model for p53 dynamics: identifying optimal therapeutic strategy for its activation and stabilization. Cell Cycle. 2009;8(22):3707-3716.
24. Terzian T, Suh YA, Iwakuma T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008;22(10): 1337-1344.
25. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J. Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem. 2001;276(9):6874-6878.
26. Candeias MM, Malbert-Colas L, Powell DJ, et al. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol. 2008;10(9): 1098-1105.
27. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell. 2009;15(3):171-183.
28. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res. 2003;1(14):1009-1016.
29. McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999; 188(3):322-328.
30. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA. 1998; 95(26):15608-15612.
31. Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008;6(6): 947-954.
32. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591-602.
33. Hu W, Feng Z, Ma L, et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res. 2007;67(6):2757-2765.
34. Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986-3996.
35. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5): 841-854.
36. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-2113.
37. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, et al. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol. 1996;180(2):129-137.
38. Møller MB, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology. 2002;41(4):322-330.
39. Rassidakis GZ, Thomaides A, Wang S, et al. p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia. 2005;19(9):1663-1669.
40. Yeudall WA, Vaughan CA, Miyazaki H, et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis. 2012;33(2):442-451.
41. Ruzov A, Shorning B, Mortusewicz O, Dunican DS, Leonhardt H, Meehan RR. MBD4 and MLH1 are required for apoptotic induction in xDNMT1-depleted embryos. Development. 2009;136(13): 2277-2286.
42. Lee IH, Kawai Y, Fergusson MM, et al. Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science. 2012; 336(6078):225-228.
43. O-charoenrat P, Sarkaria I, Talbot SG, et al. SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2. Clin Cancer Res. 2008;14(21):6780-6789.
44. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12): 1268-1286.
45. Suh YA, Post SM, Elizondo-Fraire AC, et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011;71(23):7168-7175.
46. Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001;276(48): 45255-45260.
47. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol. 2007; 27(23):8284-8295.
48. Bittenbring J, Parisot F, Wabo A, et al. MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer. 2008;8:116.
49. Hartmann E, Fernàndez V, Stoecklein H, Hernández L, Campo E, Rosenwald A. Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. Haematologica. 2007; 92(4):574-575.
50. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629.